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Abstract  
AIM: We are presenting an uncommon case of pulmonary embolism, followed with an acute myo-
cardial infarction, in a patient with progressive systemic sclerosis.  
CASE PRESENTATION: A female 40 years of age was admitted with signs of pulmonary 
embolism, confirmed with CT scan, which also reviled a thrombus in the right ventricle. The patient 
had medical history of systemic sclerosis since the age of 16 years. She suffered an ischemic 
stroke 6 years ago, but she was not taking any anticoagulant or antithrombotic medications ever 
since. She received a treatment with thrombolytic therapy, and subsequent UFH, but, on the sec-
ond day after receiving fibrinolysis, she felt chest pain accompanied with ECG changes consistent 
for ST-segment elevation myocardial infarction (STEMI). Urgent coronary angiography was 
undertaken, which reviled cloths causing total occlusion in 4 blood vessels, followed with 
thromboaspiration, but without successful reperfusion. Several hours later the patient developed 
rapid deterioration with letal ending. During the very short hospital course, blood sampling reviled 
presence of antiphospholipid antibodies.  
CONCLUSION: The acquired antiphospholipid syndrome is common condition in patients with 
systemic autoimmune diseases, but relatively rare in patients with systemic sclerosis. Never the 
less, we have to be aware of it when treating the patients with systemic sclerosis. 
 
 
 
 
 
 
 
Introduction 
 
The antiphospholipid syndrome also known 
as Hughes Syndrome is an autoimmune condition 
which is characterized by the occurrence of ve-
nous/arterial thrombosis or of specific pregnancy mor-
bidity, in the presence of antiphospholipid antibodies. 
There are three primary classes of antibodies associ-
ated with the antiphospholipid antibody syndrome: 
anticardiolipin antibodies, the lupus anticoagulant, and 
antibodies directed against specific molecules includ-
ing a molecule known as beta-2-glycoprotein. A pa-
tient with the antiphospholipid syndrome must meet at 
least one of two clinical criteria and at least one labo-
ratory criterion.  
The clinical criteria, adapted from Miyakis et 
al., 2006 [1], include:  Vascular thrombosis: one or 
more episodes of arterial, venous or small vessel 
thrombosis; and Pregnancy morbidity: at least one 
unexplained death of a normal appearance fetus, at or 
beyond the 10th week of gestation; at least one pre-
term birth of a neonate of normal appearance before 
34 weeks of gestation, because of eclampsia or se-
vere pre-eclampsia, or with signs of placental insuffi-
ciency; three or more unexplained consecutive spon-
taneous miscarriages before 10 weeks of gestation 
where anatomical, hormonal and chromosomal 
causes have been excluded.  
The laboratory criteria include: Lupus antico-
agulant (LA) present in the plasma, on two or more 
occasions at least 12 weeks apart; Anticardiolipin 
(aCL) antibody present in serum or plasma, in me-
dium or high titer (i.e. ≥ 40 GPL units or MPL units or 
≥ 99th centile), on two or more occasions at least 12 
weeks apart; and Anti-b2-glycoprotein I antibody in 
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serum or plasma (in titer ≥ 99th centile), present on 
two or more occasions, at least 12 weeks apart.  
There are two main classifications of the an-
tiphospholipid antibody syndrome. If the patient has 
an underlying autoimmune disorder, such as systemic 
lupus erythematosus, the patient is considered to 
have secondary antiphospholipid antibody syndrome. 
If the syndrome exists as an independent condition, 
than it is termed primary antiphospholipid antibody 
syndrome [1-3]. 
The aim of this study is to present an uncom-
mon case of pulmonary embolism, followed with an 
acute myocardial infarction, in a patient with progres-
sive systemic sclerosis.   
  
 
Case Presentation 
 
Medical history: A 40 year old woman has 
been suffering from progressive systemic sclerosis, 
diagnosed at the age of 16 years. She was not regu-
larly followed up, eider for regular check up’s, eider for 
medications. Her last control at the Rheumatology 
Clinic was a year ago, and since then she was on 
methotrexate (10 mg). She was married, but had 
never been pregnant. Important information from her 
previous medical history is the fact that she suffered 
an ischemic stroke 6 years ago, but a work up for hy-
percoagulability state was never conducted, and any 
prophylactic anticoagulant or antithrombotic therapy 
was not given. One week before the admission at 
Cardiology Clinic, she was hospitalized at the Rheu-
matology Clinic because of shortness of breath, 
cough, fatigue and weakness. On physical examina-
tion she was pale, with cyanosis on the both hands. 
She had pinched nose, taut skin with numerous tele-
angiectasias with retraction of the lips. On ausculta-
tion she had decreased breath sounds, absent in the 
basal parts of the right lung. Her BP was 120/80 
mmHg, and HR = 80/bpm. Laboratory tests: poly-
globulia with red blood cells 6.0 x 10
12
/L, Hb 172 g/L 
and hematocrit 0.57; moderate thrombocytopenia (50-
100 x 10
9
/L), in two separate controls, and elevated 
WBC (>20 x 10
9
/L), with neutrophilic predominance (> 
90%). Other biochemical parameters were in the nor-
mal range. The chest X-ray detected consolidation of 
the basal parts of the right lung, accompanied with 
deteriorated respiratory function (blood gas analyses 
revealed partial respiratory insufficiency: pH 7.446; 
pCO2 4.06 kPa; pO2 6.99 kPa; sO2 88%). At that point 
the patient was treated with corticosteroids, antibiot-
ics, bronchodilators and oxygen therapy. After several 
days she experienced sudden onset of sharp chest 
pain, shortness of breath, cough, rapid heartbeat and 
central cyanosis.  
 
Figure 1: Cardiac CT showing extensive thrombotic material in right 
ventricle (RV), small bilateral pleural effusions, and tiny layer of 
pericardial effusion 
 
Because of a suspicion of pulmonary throm-
boembolism (PTE), D-dimers were measured, and 
found to be increased (> 4500 ng/mL), and CT scan 
with pulmonary embolism protocol was performed. It 
reviled multiple thrombi in the right ventricle (Figure 
1), and massive acute pulmonary embolism involving 
the right pulmonary artery and extending into the lobar 
and segmental brunches. Truncus pulmonalis was 
dilated up to 40 mm in diameter; same was with the 
right PA, 28mm (Figure 2).  
 
Figure 2: Cardiac CT of the truncus pulmonalis (TP) and principal 
branches: dilated TP (40mm), dilated RPA (28mm), thrombotic 
material in TP, massive occlusive thrombus in RPA, and multiple 
thrombi in secondary branches 
 
We also registered small bilateral pleural effu-
sion and tiny layer of pericardial effusion (Figure 1). 
CT scan and transthoracic echocardiography (TTE), 
indicated dilated right heart cavities, severe tricuspid 
valve regurgitation, pulmonary hypertension, McCon-
nell's sign - all together manifestations of right ven-
tricular dysfunction were present, as a result of mas-
sive pulmonary thromboembolism, at which point de-
cision for treatment with fibrinolysis was made. There 
was demonstrating signs of severe illness: was dysp-
neic, tachypneic, with low sO2 saturation (~76% with 
oxygen mask) and central cyanosis, but hemodynami-
cally stable: HR ~80/bpm, BP 120/80 mmHg. The 
ECG showed sinus rhythm with signs of right axis de-
viation and incomplete RBBB (Figure 3A).  
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Figure 3: Patient’s ECG at the moment of diagnosis of BTE: sinus 
rhythm, 70 bpm, no typical ECG signs for BTE. (A) ECG during 
sudden chest pain on the second day after she was treated with 
thrombolytic therapy: sinus tachycardia, 100/bpm, ST-segment 
elevation in lateral leads: D1 and AVL, RBBB (B) 
 
Thrombolytic treatment with streptokinase 
was applied, using the 24 h administration protocol 
(250 000 IU during the first hour, followed by 100 000 
IU/h in the next 24 hours), with subsequent heparin 
(UFH) infusion (1000 IU/h). At the very beginning of 
the UFH infusion, in the morning hours on the second 
day of the PTE treatment, she again felt chest pain, 
but now clamping, accompanied with ST elevation in 
the lateral leads (D1 and AVL), and broad QRS com-
plex (~120 msec), consistent for STEMI (Figure 3B). 
The patient was immediately sent to the cat lab, 
where coronarography was performed. The angio 
study revealed 4 occluded arteries (left anterior de-
scending artery, diagonal branch, circumflex artery 
and obtuse marginal artery). The only potent one was 
the right coronary artery. An attempt for thromboaspi-
ration on the left anterior descendent artery and its 
diagonal branch was undertaken, clot was aspirated 
from LAD and diagonal brunch, but the TIMI flow re-
mained low (Figure 4).  
 
Figure 4: Coronary angiography, only the LAD (left panel – A), and 
the diagonal branch (right panel B) are presented. These are post 
thromboaspiration results (unsuccessful reperfusion) 
 
Despite all the efforts, 20 hours after the in-
tervention, the patient died in cardiogenic shock. 
Blood sampling for the acquired antiphospholipid syn-
drome, that we performed, were positive for anticardi-
olipin (aCL) antibodies. It was the first and only time 
that suspicion for antiphospholipid syndrome was 
arisen in this patient with the history for progressive 
systemic sclerosis.  
 
 
Discussion 
 
Today, the cause of the antiphospholipid syn-
drome is still not well understood. Although the aPL 
antibodies are clinically linked to APLs, it is not known 
whether they are involved in pathogenesis, because 
about 5% of the healthy population, has aPL antibod-
ies. There are several mechanisms which could be 
responsible for the hypercoagulability state, including: 
complement activation, production of antibodies 
against coagulation factors (prothrombin, protein C, 
protein S), platelet activation, activation of the vascu-
lar endothelium, reaction of antibodies to oxidized low 
density lipoprotein [1-4].  
The diagnosis of an antiphospholipid syn-
drome requires the combination of at least one clinical 
and one laboratory criterion, but timing of the labora-
tory test and clinical event is very important. A remote 
test, avoids false positive results from interference 
with the event, however, in extreme cases, a positive 
test separated many years from a clinical manifesta-
tion also risks misclassification, as a causative rela-
tionship between event and test would then be in 
doubt. The Sapporo statement encouraged investiga-
tors to provide applicable information, but relevant 
existing data are rather poor. The stability of the labo-
ratory testing over time is reassuring, but spontaneous 
variation of aPL in individual patients occurs in up to a 
quarter of cases. Whether disease activity and treat-
ment contribute to assay variability is unknown. The 
International consensus statement from 2006, sug-
gests that APS should not be classified, if it is more 
than 5 years between the clinical event and the posi-
tive laboratory test, and that an allowance of at least 
12 weeks between symptom and test will assist as-
sessment of the relationship between clinical manifes-
tations and aPL. The time limits are valid independ-
ently of which feature of APS (clinical or laboratory) 
occurs first [1].  
Except these criteria, adapted from Miyakis, 
there is a list of other features which are associated 
with APS but are not included in the revised classifica-
tion. These include: heart valve disease, livedo reticu-
laris, thrombocytopenia, nephropathy, neurologic in-
volvement, IgA aCL, IgA anti-beta-2-GPI antibodies, 
antiphosphatidylserine antibodies, antiphosphati-
dylethanolamine antibodies, antibodies against 
prothrombin alone, and antibodies to the phosphati-
dylserine-prothrombin complex [1].  
In our patient we had at list three episodes of 
vascular thrombosis (arterial), including cerebrovascu-
lar insult 6 years earlier. We managed to have only 
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one laboratory sampling of APLa, during the actual 
hospitalization (high positive - 87 GPL units). We were 
unable to trace any documentation for previous test-
ing, partly because of a lack of patient cooperation 
and adherence to the medical treatment of the dis-
ease. She also had heart valve disease on the mitral 
valve leaflets, and moderate thrombocytopenia.  
We are aware that we don’t fulfil exactly the 
laboratory criteria, because of the course of the dis-
ease we were unable to perform all the necessary 
laboratory investigations, but according to results of 
one blood sampling and clinical characteristics we 
strongly believe that our patient was suffering from an 
antiphospholipid syndrome secondary to systemic 
sclerosis, experiencing catastrophic complications.  
The connective tissue disorders comprise a 
number of related conditions that include systemic 
lupus erythematosus (SLE), the antiphospholipid 
(Hughes) syndrome, scleroderma, myositis and 
Sjögren's syndrome. They are characterized by 
autoantibody production and other immune-mediated 
dysfunction. There are common clinical and serologi-
cal features with some patients having multiple over-
lapping connective tissue disorders. There are grow-
ing evidences about the association of APL syndrome 
with systemic sclerosis. It is not exclusively associated 
with systemic lupus or rheumatoid arthritis [5].  
In the study conducted by Say and Swetha, 
published in 2015, the association of antiphospholipid 
antibodies was found for several connective tissue 
diseases. 14.7 % of patients with connective tissue 
disease had positive APLa, mostly in SLE group 
(73.3% of positive pts.), but also in 13.3% of patients 
with mixed connective tissue disease (MCTD) and 
13.3% of patients with systemic sclerosis. In conclu-
sion they recommend that APL antibodies should be 
tested in all patients with connective tissue disease 
[6]. Balanescy and co-workers conducted a study 
about the association of systemic sclerosis (SSc) and 
APLa. 38.9% of patients with SSc had antiphosphol-
ipid antibody presence associated with low comple-
ment level, in the absence of any clinical feature of 
APLs. Toure, in his study of 40 pts with SSc identified 
APLa in 57.3% of them [7, 8]. 
Clinical significance of our finding: The par-
ticular role of these antibodies in clinical manifesta-
tions of SSc is still unknown [7]. Searching threw the 
literature; we found a case report on association of 
APLs with cutaneous systemic sclerosis (SSc), with 
vascular complications that responded well to oral 
anticoagulant treatment (OAK) [9]. Also, a compli-
cated case of vascular complication after CABG in 
patient with SLE, SSc and secondary APLs was re-
ferred by Naoto in 2011 [10]. In the study cohort of 72 
pts with SSc, 9.7% were positive to APLa, but only 
one patient had deep vein thrombosis [11]. We were 
not able to find case reports on SSc associated with 
APLs, with similar vascular distribution (in arterial bed) 
as in our patient. Is it only overlapping, or one condi-
tion is leading to other, with catastrophic outcome? 
Would our patient have different outcome if the proper 
diagnostic workup has been undertaken after the first 
thrombotic event?  
According to the recommendations, the labo-
ratory testing should have been done after the first 
episode of thrombotic event (the ischemic stroke). The 
confirmation of the diagnosis of APLs at that point, 
would mean a proper anticoagulation treatment, which 
could have prevented the further thrombotic complica-
tions and fatal consequences in this patient.  
In conclusion, according to our case, and 
growing body of the literature data, it seems reason-
able that patients with SSc should be investigated for 
APLa, in order to early identify those who have in-
creased risk for worse clinical outcome, and to expose 
them to more aggressive treatment.  
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